EMA Proposal Would Give Popular Alternative For Pharmaceutical Water A Foothold in Europe
Executive Summary
The European Medicines Agency is inviting stakeholder feedback on a proposal to allow reverse osmosis as an alternative to steam distillation for making water for injections (WFI) for pharmaceutical manufacturing. EMA also would expand its water quality guideline to cover vaccines and advanced therapy medicinal products such as cell and gene therapies.
You may also be interested in...
EMA Heeds Calls To Relax Water Quality Threshold For Active Substance Fermentation Media
The European Medicines Agency’s first revision of its water quality guideline in 18 years has been updated to reflect current expectations for the minimum acceptable quality of water used in the manufacture of active drug substances and finished drug products.
Industry Guide Could Ease EU Adoption Of Reverse Osmosis For Pharmaceutical Water
Recent guidance from a pharmaceutical industry group should help manufacturers in the EU make the transition from using highly purified water and steam distillation to other methods for preventing microbiological contamination of pharmaceuticals such as reverse osmosis. The guideline also addresses the cost of using membrane technology versus distillation technology.
Quality Regulatory Updates In Brief: EMA, FDA, EDQM And WHO
EMA proposes updating methods for water for injection; FDA clarifies policies on first responders under new drug tracing law; EDQM lists top 10 API deficiencies; and WHO invites API manufacturers to participate in prequalification program.